Investment Thesis
CorMedix demonstrates exceptional fundamental strength with 617% revenue growth, outstanding profitability margins (82.5% gross, 50% operating, 30.3% net), and fortress-like financial health (zero debt, $178M cash, 2.98x current ratio). Strong free cash flow generation (32.7% FCF margin) and sustainable operating leverage validate earnings quality, though extraordinary growth rates and low ROE/ROA metrics warrant monitoring for sustainability.
Strengths
- Exceptional YoY revenue growth of 617% with 780% EPS growth demonstrating strong operating leverage
- Outstanding profitability: 82.5% gross margin, 50% operating margin, 30.3% net margin with $38.6M net income
- Fortress balance sheet: zero long-term debt, $178.1M cash, 2.98x current ratio, 0.00 debt/equity ratio
- High-quality earnings: 32.7% free cash flow margin with minimal capex ($729K) shows cash generation efficiency
Risks
- Sustainability risk: 617% revenue growth is extraordinarily high and may not be repeatable in future periods
- Capital efficiency concern: despite high margins, ROE of 8.8% and ROA of 4.7% suggest inefficient asset/equity deployment
- No insider buying activity in last 90 days (0 Form 4 filings) could indicate mixed management conviction
- Pharmaceutical sector competition and regulatory risks inherent to SIC 2834 industry
Key Metrics to Watch
- Gross margin sustainability and potential compression from current 82.5% level in future quarters
- Revenue growth deceleration rate - critical to assess if 617% can be maintained or normalizes significantly
- Return on Equity (ROE) trend and management's capital allocation strategy to improve utilization efficiency
- Operating cash flow consistency and free cash flow margin maintenance as revenue normalizes
- Product concentration and new revenue drivers - confirm growth is diversified, not single-product dependent
Financial Metrics
Revenue
127.4M
Net Income
38.6M
EPS (Diluted)
$0.43
Free Cash Flow
41.7M
Total Assets
815.6M
Cash
178.1M
Profitability Ratios
Gross Margin
82.5%
Operating Margin
50.0%
Net Margin
30.3%
ROE
8.8%
ROA
4.7%
FCF Margin
32.7%
Balance Sheet & Liquidity
Current Ratio
2.98x
Quick Ratio
2.74x
Debt/Equity
0.00x
Debt/Assets
46.4%
Interest Coverage
3,883.72x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T06:48:38.143349 |
Data as of: 2026-03-31 |
Powered by Claude AI